Monday, June 17th 2002

● 8.00 a.m. Words of welcome by the local Organizing Committee
   Download the program of the day:

● 8.15 a.m. PLENARY SESSION 1: GENETICS
   Room "Grands Lacs Baïkal-Victoria"
   CHAIRPERSONS: G. BRODEUR and M. SCHWAB
   (see details)

● 10.30 a.m. Break
   Coffee & Viennoiserie

● 11.00 a.m. PLENARY SESSION 2 : BIOLOGY
   Room "Grands Lacs Baïkal-Victoria"
   CHAIRPERSONS: S. COHN and H. CARON
   (see details)

● 12.40 p.m. Lunch time
   Room "Les Parcs"

● 2.00 p.m. PARALLEL SESSION 1: GENETICS
   Room "Grands Lacs Baïkal-Victoria"
   CHAIRPERSONS: O. DELATTRE and R. VERSTEEG
   (see details)

● 5.00 p.m. to 7.00 p.m. Posters
   Room "Léman": Biology (30 Posters) (see details)
   Chair: G. Brodeur and J. Michon
   Room "Lugano-Constance": Translational Research (70 Posters) (see details)
   Chair: K. Matthay and D. Plantaz

● 7 to 9 p.m. Wellcome ceremony

Tuesday, June 18th 2002

● 8.00 a.m. Words of welcome by the local Organizing Committee
   Download the program of the day:

● 8.15 a.m. PLENARY SESSION 3 : BIOLOGY AND TRANSLATIONAL
   Room "Grands Lacs-Baïkal-Victoria"
   CHAIRPERSONS: J MARIS and PF. AMBROS
   (see details)
10.30 a.m. Break
Coffee & Viennoiserie

11.00 a.m. PLENARY SESSION 4: BIOLOGY AND TRANSLATIONAL
Room "Grands Lacs-Baïkal-Victoria"
CHAIRPERSONS: NK CHEUNG and GP TONINI
(see details)

12.40 p.m. Lunch time
Room "Les Parcs"

2.00 p.m. PARALLEL SESSION 3: TRANSLATIONAL
Room "Grands Lacs-Baïkal-Victoria"
CHAIRPERSONS: M. HABER and D. VALTEAU-COUANET
and T. PHILIP and A. EVANS after the break
(see details)

2.00 p.m. PARALLEL SESSION 4: CLINICAL
Room "Michigan"
CHAIRPERSONS: F. BERTHOLD and JM. ZUCKER
and B DE BERNARDI and H. RUBIE after the break
(see details)

5.30 p.m. to 7.15 p.m. Posters
Room "Léman": Genetics (29 Posters) (see details)
Chair : S. Cohn and J. Bénard
Room "Lugano-Constance": Clinical Research (55 Posters) (see details)
Chair : T. Sawada and R. Ladenstein

8 p.m. Galla dinner

Wednesday, June 19th 2002

8.00 a.m. Words of welcome by the local Organizing Committee
Download the program of the day:

8.15 a.m. PLENARY SESSION 5: TRANSLATIONAL
Room "Grands Lacs-Baïkal-Victoria"
CHAIRPERSONS: K. MATTHAY and A. PEARSON
(see details)

10.15 a.m. Break
Coffee & Viennoiserie

11.00 a.m. PLENARY SESSION 6: CLINICAL
Room "Grands Lacs-Baïkal-Victoria"
CHAIRPERSONS: O. HARTMANN and R. SEEGER
(see details)

12.15 p.m. G. BRODEUR: CLOSING REMARKS
PLENARY SESSION 1: GENETICS

8.00 a.m. CHAIRPERSONS: G. BRODEUR and M. SCHWAB
Room "Grands Lacs Baïkal-Victoria"

8.15 a.m. Genetic Analysis of Tumors in a Mouse Model for Neuroblastoma
University of California, San Francisco, CA, USA

8.35 a.m Functional Genomics Approach to Understanding of the Genesis and Biology of Neuroblastoma Based on the Mass Cloning of 7,000 Genes from Three Clinically Different Subsets
Chiba Cancer Center Research Institute, Chiba, National Institute of Neuroscience, Tokyo, and Gunma University School of Medicine, Gunma, Japan

8.55 a.m Positional Candidate Analysis of Neuroblastoma Suppressor Genes within 1p36.2-p36.3
OG-03 Gotoh T, Thompson PM, Kok M, Maris JM, White PS, Brodeur GM.
The Children's Hospital of Philadelphia, Philadelphia, PA, USA

9.15 a.m. A Functional and Expression Profiling Strategy for Isolating Neuroblastoma (NB) Suppressor Genes on Chromosome 11
Children's Hospital of Philadelphia and Children's Oncology Group, USA

9.45 a.m. Constitutional Mutations in the Glial Family Ligands GDNF and ARTN Predispose to the Development of Neuroblastoma
OG-07 Forsyth J & McConville C.
University of Birmingham & Birmingham Children's Hospital, UK

10.05 a.m. The Wiring of Neuroblastomas
Academic Medical Centre, Amsterdam, The Netherlands; Max Planck Institute, Berlin, Germany

10.30 a.m. Break
Coffee & Viennoiserie
PLENARY SESSION 2 : BIOLOGY

11.00 a.m.  CHAIRPERSONS: S. COHN and H. CARON
Room "Grands Lacs Baïkal-Victoria"

11.00 a.m.  Expression of BIN1, a Putative MYCN-Interacting Tumor Suppressor, is
Reduced in Neuroblastomas with Unfavorable Biologic Features

The Children's Hospital of Philadelphia, PA, USA; Kyushu University, Japan

11.20 a.m.  Downregulation of N-myc Reduces Neuroblastoma Tumorigenesis in a
Transgenic Mouse Model

OB-02 Haber M, Burkhart C, Marshall GM, Weiss WA, Norris MD.
Children's Cancer Institute Australia for Medical Research, Sydney, Australia
and University of California San Francisco, CA, USA

11.40 a.m.  Minichromosome Maintenance Protein MCM7 is a Direct Target of the
MYCN Transcription Factor in Neuroblastoma

OB-03 Shohet JM, Hicks MJ, Plon SE, Burlingame SM, Stuart S, Chen SY, Brenner
M and Nuchtern JG.
Baylor College of Medicine; Children's Hospital, Houston, Texas; Palo Alto,
California, USA

12.00 a.m.  Expression Profiling of TrkB Transfected Neuroblastoma Cells Reveals
Cadherin 11 and MCSP as Potential New Target Genes of TrkB/BDNF
Signaling

University Children's Hospital of Essen, Germany and The Children's Hospital
of Philadelphia, PA, USA

12.20 p.m.  Identification and Characterisation of Apoptosis-Sensitizing Genes in
Neuroblastoma

OB-05 Wittke I, Wiedemeyer R, Savelyeva L and Schwab M.
Deutsches Krebsforschungszentrum Heidelberg, Germany

12.40 p.m.  Lunch
Room "Les Parcs"
PARALLEL SESSION 1: GENETICS

2.00 p.m. CHAIRPERSONS: O. DELATTRE and R. VERSTEEG
Room “Grands Lacs Baikal-Victoria”

2.00 p.m.
Construction and Clinical Use of the Neuroblastoma cDNA Microarray for Predicting the Prognosis
OG-08
Ohira M, Morohashi A, Hamano S, Machida T, Aoyama M, Fukumura M, Miyazaki K, Isogai E, Akazawa C, Kousaka S, Hirato J, Nakagawara A. Chiba Cancer Center Research Institute, Chiba., National Institute of Neuroscience, Tokyo, Gunma University, School of Medicine, Gunma, Japan

2.15 p.m.
Gene Expression Profiling of Progressing Versus Regressing Neuroblastomas with cDNA Microarrays
OG-09

2.30 p.m.
Micro-Array Analysis of Neuroblastoma Tumor Samples: High Expression of Immunity-Related Genes in Low Risk Tumors
OG-10
Alaminos M, Cheung NKV, Mora J, Qin J, Smith A, Gerald WL. Memorial Sloan-Kettering Cancer Center, New York, NY, USA

2.45 p.m.
Subtractive Expression Profiling between Two Genetic Subgroups of Neuroblastoma
OG-11
Vandesompele J, Pattyn F, De Preter K, Van Roy N, Swerts K, Hoebeeck J, Laureys G, De Paepe A, Philippe J, Speleman F. Center for Medical Genetics, Ghent University Hospital, Belgium

3.00 p.m.
Forward Genetic Screens for Mutations Affecting the Development of the Peripheral Sympathetic Nervous System in the Zebrafish Model
OG-12
George R, Rauh-Adelmann C, Grant A, Kanki J, Rhodes J, Palomero T, Look AT. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

3.15 p.m.
Deletion Mapping and Mutation Analysis of 11q23 in non-MYCN Amplified, Intermediate Type of Neuroblastoma
OG-13
Arai Y, Kubo T, Gamou T, Hosoda F, Sakiyama T, Toyoda A, Hattori M, Sakaki Y, Ohira M, Nakagawara A, Ohki M. National Cancer Center Research Institute., Tokyo; RIKEN Genomic Sciences Center, Yokohama; Chiba Cancer Center Research Institute, Chiba, Japan

3.30 p.m.
Break
Coffee & vienoiseries

4.00 p.m.
A Constitutional Translocation t(1;17) in a Neuroblastoma Patient Disrupts a Novel Candidate Tumor Suppressor Gene
OG-14
Vandepoele K, Staes K, Van Roy N, Berx G, Speleman F, Van Roy F. Ghent University Hospital, Ghent, Belgium

4.15 p.m.
No Evidence for Impriting at Chromosome Subband 1p36.3 in Neuroblastoma
OG-15
Winter CL, Maris JM, Liu X, Guo C, Look AT, White PS, Brodeur GM and Hogarty MD. Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA; Dana Farber Cancer Institute, Boston, MA; Children’s Oncology Group, USA

4.30 p.m.
Analysis of Genes Down Regulated by N-myc in Neuroblastoma
OG-16  Valentijn LJ, van Asperen R, Schwab M, and Versteeg R. 
Academic Medical Center, Amsterdam, the Netherlands, German Cancer 
Center, Heidelberg, Germany
PARALLEL SESSION 2 : BIOLOGY

2.00 p.m. CHAIRPERSONS: P. KOGNER and A. NAKAGAWARA
Room "Michigan"

2.00 p.m. Loss of One HUD Allele on Chromosome 1p is Linked to Amplification of N-myc in Human Neuroblastoma Cells
OB-06 Ross RA, Lazarova DL, Barton KB, Biedler JL, Spengler BA.
Fordham University, Bronx, NY USA

2.15 p.m. Np73, Mapped to 1p36 2-3, Induces Its Own Splicing Variant DeltaNp73, Which Negatively Regulate p53 and p73 Function by Promoting Cell Survival in SH-SY5Y Neuroblastoma Cells Treated with Cisplatin: Identification of p73-Specific Target Element within the deltaNp73 Promoter
OB-07 Nakagawa T, Takahashi M, Ozaki T, Watanabe K, Hayashi S, Hosoda M, Todo S, and Nakagawara A.
Chiba Cancer Center Research Institute, Chiba, Hokkaido University School Medicine, Sapporo, Japan

2.30 p.m. Nuclear p53 Expression is Associated with High-Risk, Undifferentiated Neuroblastoma, p21 WAF1 Expression, MYCN Amplification and MYCN Expression
University of Newcastle, Sheffield Children's Hospital and St James's University Hospital, Leeds, U.K.

2.45 p.m. Distinct Mechanisms of Cell Cycle Arrest Control the Decision between Differentiation and Senescence in Neuroblastoma
OB-09 Lasorella A and Iavarone A.
Cancelled Albert Einstein College of Medicine, New York, NY, USA

3.00 p.m. Activin A Expression Impairs the Malignant Potential of Neuroblastoma Cells in Vitro and in Vivo
OB-10 Schweigerer L, Breitbart S, Fotsis T, Schramm A.
University Children's Hospital of Essen, Germany

3.15 p.m. Differences in Neurotrophin-Mediated Signal Transduction and Early Gene Induction in Human Neuroblastoma (NB) Cells Expressing TrkA or TrkB
OB-11 Minturn JE, Hishiki T, Ho R, Ikegaki N, Brodeur GM.
Children's Hospital of Philadelphia, PA USA

3.30 p.m. Break
Coffee & vienoiseries

4.00 p.m. Schwann Cells Produce a Spectrum of Factors that Induce Endothelial Cell Apoptosis and Inhibit Angiogenesis
OB-12 Chlenski A, Crawford SE, Salwen HR, and Cohn SL
Northwestern University, Chicago, IL, USA

4.15 p.m. Nestin is a Potential Mediator of N-myc Activity in Human Neuroblastoma
OB-13 Thomas S, Spengler BA, Messam CA, Biedler JL, Ross RA.
Fordham University, Bronx, NY, and NINDS, NIH, Bethesda, MD, USA

4.30 p.m. Rapamycin Inhibits Growth of Human Neuroblastoma Cells without Suppression of N-Myc Induction
OB-14 Misawa A, Hosoi H, Tsuchiya K, and Sugimoto T.
Department of Pediatrics, Kyoto Prefectural University of Medicine, Japan
POSTER SESSION 1: BIOLOGY

CHAIRPERSONS: R. CASTELBERRY and J. MICHON
Room "Leman"

**PB-01** Murine neuroblastoma models featuring regulable MYCN expression and markers for early tumor detection
Chesler L, Weiss WA.
UCSF, San Francisco, CA, USA

**PB-02** Expression Analysis on Normal Neuroblasts Isolated from Fetal Adrenals Using Laser Capture Micro-Dissection
Ghent University Hospital, Ghent, University Hospital Erasme, Brussels, and Middelheim Hospital, Antwerp, Belgium

**PB-03** Distinct Cytogenetic Pathways of Advanced Stage Neuroblastoma Detected by Spectral Karyotyping
Stark B, Jeison M, Bar-Am I, Galser-Gabay L, Mardoukh J, Goshen Y, Stein J, Zaižov R, Yaniv I. Schneider Children's Medical Center of Israel, Petah-Tikva, Sackler Faculty of Medicine, Tel Aviv University and Applied Spectral Imaging, Migdal Haemek, Israel

**PB-04** Ectopic Expression of MCYN Enhances the Proliferation Effect of Neurotrophins in SH-SY5Y Neuroblastoma (NB) Cells
Hishiki T, Ho R, Minturn JE, Ikegaki N, Brodeur GM.
The Children's Hospital of Philadelphia, Philadelphia, USA

**PB-05** Does DDX1 co-amplification with MYCN have a role in neuroblastoma?
Elsden JL, Kenyon RM, George RE, Godbout R, Pearson ADJ and Lunec J.
University of Newcastle upon Tyne, Newcastle upon Tyne, UK

**PB-06** Deregulated MYCN Induces Apoptosis in Primary Human Cells of Neuroectodermal Origin
Liu X, Tajiri T, Dam V, Hogarty MD.
The Children's Hospital of Philadelphia, USA

**PB-07** ID2 is a MYCN Target Gene, but Expression is not Correlated with MYCN Gene Amplification in Human Neuroblastomas

**PB-08** Id Proteins in Human Neuroblastoma Cells: Expression and Interaction with Neuronal bHLH Proteins.
Persson P, Jögi A, Grynfeld A, Påhlman S, and Axelson H.
Lund University, University Hospital MAS, Malmö, Sweden

**PB-09** The Role of the Chromosome 17q Genes nm23-H1 and nm23-H2 in Neuroblastoma
Godfried MB, van Sluis P, Versteeg R and Caron HN.
Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

**PB-10** E-box Mediated Regulation of the MRP Promoter in Human Neuroblastoma
Manohar CF, Bray JA, Salwen H, Norris MD, Haber M, and Cohn SL.
Departments of Pediatrics and The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Chicago, IL, USA and the Children's Cancer Institute Australia for Medical Research, Sydney, Australia
Attenuated G1 Arrest in Neuroblastoma is Mediated by Differential Localization of Cdk2 and p21Waf-1/Cip-1
McKenzie PP, Danks MK, Harris LC.
St. Jude Children's Research Hospital, Memphis, TN, USA

The p53 Gene is Frequently Mutated in Cell Lines but not in Fresh Tumors of Neuroblastoma within All Coding Sequences
Tanaka K, Takita J, Taketani T, Hanada R, Yamamoto K, Hashizume K, and Hayashi Y.
University of Tokyo Hospital, Tokyo, and Saitama Children's Medical Center, Saitama, Japan

The Transcription Factor HAND2 Regulates the Development in Neuroblastoma Cells
Morikawa Y, Hwang S, Chun S, Venuti J and Cserjesi P.
Columbia University, New York, NY, and Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA

Delta-Notch Signaling in Neuroblastoma Differentiation
Van Limpt V, Chan A, Caron H, van Sluis P and Versteeg R.
Academic Medical Center, Amsterdam, The Netherlands

The NOTCH-1 Signalling Cascade in Differentiating Neuroblastoma Cells
Stockhausen M, Axelson H.
Unit for Molecular Medicine, MAS, Lund University, Malmö, Sweden

Induction of Galanin Receptor Subtype 3 Expression Leads to Morphological Changes in the Neuroblastoma Cell Line SH-SY5Y
Berger A, Sperl W, Kofler B.
Children's Hospital, Salzburg, Austria

Galanin and Galanin Receptor Expression in Neuroblastic Tumours : Correlation with their Differentiation Status
Perel Y, Amrein L, Dobremetz E, Rivel J, Daniel JY, Landry M.
University of Bordeaux 2, Children's Hospital, University Hospital, Bordeaux, France

Expression of Pax5 in N-type Neuroblastoma Cell Lines
Baumann FB, Himmelmann A.
University Hospital, Zurich, Switzerland

Neuroblastoma and the PML Nuclear Body (NuB)
Bloch DB, Nakajima A, Yu J, Nakajima H, Diller LR, Bloch KD.
Harvard Medical School, Boston, MA, USA

Unveiling the Apolipoprotein J Signalling Network: Implications for Neuroblastoma Cell Survival
Pagnan G, Santilli G, and Sala A.
The Institute of Child Health, London UK; Section of Medical Oncology, Chieti, Italy

BTG2TIS21PC3 Induces Neuronal Differentiation and Prevents Apoptosis of Terminally Differentiated PC12 Cells
Centre Léon Bérard, Lyon, France

Signal Transduction Pathways Through TRK-A Receptors in Neuroblastoma Cell Lines and Primary Tumor Tissues
Sugimoto T, Kuroda H, Moritake H, Horii Y, Tajiri T, Suita S, Fukushige T, Takamatsu H.
Kyoto Prefectural University of Medicine; Miyazaki Medical College; Kyushu University; Kagoshima University, Japan

The p73 Target Genes in Human Malignant Neuroblasts are Related to Neuronal Development and Sympathetic Differentiation

PB-24 Ataxin2 Sensitizes Neuroblastoma Cells for Apoptosis
Wiedemeyer R, Westermann F, Wittke I and Schwab M. German Cancer Research Center

PB-25 Multiple Mechanisms Prevent MHC-Class II Expression in NB
Croce M, De Ambrosis A, Corrias MV, Accolla RS, Occhino M, Mazza S, Meazza R, Pistoia V, and Ferrini S. Istituto Nazionale per la Ricerca sul Cancro, Istituto G. Gaslini, Genoa; Università della Insubria Varese; Italy

PB-26 Intercellular Adhesion Molecule-2 (ICAM-2) Expression in Neuroblastoma
Danks MK, Davidoff AM, Potter PM. St. Jude Children's Research Hospital, Memphis, TN, USA

PB-27 I-Type Stem Cells are Components of Human Neuroblastoma Tumors as well as Cell Lines
Spengler BA, Walton JD, Biedler JL, Mora J, Gerald WL, Cheung N-KV, Ross RA. Fordham University, Bronx NY and Memorial Sloan-Kettering Cancer Center, New York, NY, USA

PB-28 A Possible New Role for Filamins in Natural Human IgM-mediated Apoptosis in Neuroblastoma
Bachmann AS, Heiligtag S, Howard JP, David K, and Vogel CW. Cancer Research Center of Hawaii, University of Hawaii, Honolulu, Hawaii, USA

PB-29 Hypoxic Treatment of Human Neuroblastoma Cells Alters the Gene Expression toward a More Immature Phenotype
Jogi A, Øra I, Nilsson H, Poellinger L, Axelson H and Påhlman S. Lund University, CMB, Medical Nobel Institute, Karolinska Institute, Sweden

PB-30 Phenotypic changes in human neuroblastoma cells induced by hypoxia and hypoglycemia
Nilsson H, Jogi A, Påhlman S. Lund University, University Hospital MAS, Malmö, Sweden
POSTER SESSION 2 : TRANSLATIONAL

CHAIRPERSONS: K. MATTHAY and D. PLANTAZ
Room "Lugano-Constance"

- **PT-01** Neurotrophin Receptors TrkA and TrkB Both Enhance Survival of Irradiated Neuroblastoma Cells, Probably Using Different Mechanisms
  University Children's Hospital of Essen, Germany and The Children's Hospital of Philadelphia, Philadelphia PA, USA

- **PT-02** 17q Gain - a Genetic Marker Independent from Diploidy?
  Stock C, Luegmayr A, Vallant E, Ladenstein R, Ambros PF, Ambros IM.
  CCRI, St. Anna Kinderspital, Vienna, Austria

- **PT-03** Expression of P27<sub>KIP1</sub> is Prognostic and Independent of MYCN Amplification in Human Neuroblastoma.
  University Children's Hospital, and Institute of Molecular Biology and Tumour Research, Marburg, Germany

- **PT-04** Automatic Quantification of MYCN Amplification in Clinical Samples
  Narath R, Ambros PF.
  CCRI, St. Anna Kinderspital, Vienna, Austria

- **PT-05** Impact of Apo3 and Apo3-Ligand Expression on Patient Survival in Primary Neuroblastomas
  Eggert A, Grotzer MA, Zuzak TJ, Ikegaki N, Zhao H, Brodeur GM.
  University Children's Hospital of Essen, Germany, University Children's Hospital of Zurich, Switzerland and The Children's Hospital of Philadelphia, USA

- **PT-06** Gene Expression Profiling in Neuroblastoma: Biological Insights and Clinicopathologic Correlation
  Hill DA, Riedley SE, Yeoh AEJ, Shurtleff SA, Patel DH, Williams WK, Pappo AS, Downing JR.
  St. Jude Children's Research Hospital, Memphis, TN, USA

- **PT-07** Elevated Level of Serum Middkine Is Significantly Correlated with Advanced Stages, Older Age, MYCN Amplification, Decreased Expression of TrkA and Diploid Karyotype in Human Neuroblastomas
  Kadomatsu K, Ikematsu S, Muramatsu H, Takei Y, Sakuma S, Nakamura Y, Muramatsu T, and Nakagawara A.
  Nagoya University School of Medicine, Nagoya; Pharmaceutical Development Department, Meiji Milk Products Co., Ltd., Odawara ; Chiba Cancer Center Research Institute, Chiba; Japan

- **PT-08** Prospective Validation of Real-Time Quantitative PCR for Detection of MYCN Amplification in Primary Neuroblastoma Specimens
  Children's Hospital of Philadelphia and University of Pennsylvania, Dana Farber Cancer Institute and Children's Oncology Group, USA

- **PT-09** Novel Human Nbla0761/hRIM1, a Gene of the Synaptic Rab3-Interacting Molecule, is Expressed Significantly at High Levels in Neuroblastomas with Favorable Outcome
Aoyama M, Asai K, Ohira M, Shishikura T, Kawamoto T, Inuzuka H, Hirato J and Nakagawara A. Chiba Cancer Center Research Institute, Chiba; Nagoya City University Medical School, Nagoya; Gunma University School of Medicine, Maebashi; Japan

PT-10 Role of the Candidate Tumor Suppressor ING1 in Neuroblastoma and Identification of the ING1 Target Genes Using Genetic Suppressor Element Procedure and cDNA Microarray
Takahashi M, Ozaki T, Nakagawa T, Watanabe K, Hayashi S, Hosoda M, Ohira M, Seki N, Mizuguchi H, Hayakawa T, Todo S, and Nakagawara A. Chiba Cancer Center Research Institute, and Helix Research Institute, Chiba; Hokkaido University School of Medicine, Sapporo; National Institute of Health Science, Tokyo; Japan

PT-11 The Primary Culture of 195 Neuroblastomas: Functional Responsiveness to NGF, but not Retinoic Acid or GDNF family factors, is Significantly Associated with Favorable Outcome
Nakanishi H, Ueda K, Sugimatsu N, Nakamura Y, Isogai E, Takada N, Kuno T, Takayasu H, Hashizume K, and Nakagawara A. Chiba Cancer Center Research Institute, Chiba; University of Tokyo, Tokyo; Kurume University School of Medicine, Kurume; Japan

PT-12 MYCN Overexpression Drives Chemoresistance in Human Metastatic Neuroblasts

PT-13 Genetics groups of Neuroblastoma Patients Defined by Molecular and Conventional Cytogenetics
Glaser-Gabay L, Jeison M, Mardouk J, Lurio D, Stein J, Goshen Y, Zaizov R, Yaniv I, Stark B. Schneider Children's Medical Center of Israel, Sackler School of Medicine, Tel-Aviv University, Israel

PT-14 Differential Gene Expression Profiles of Favorable and Unfavorable Neuroblastomas
Ishii M, Takita J, Shuichi T, Hanada R, Yamamoto K, Tanaka Y, Hayashi Y and Aburaitani H. University of Tokyo, Tokyo; Saitama Children's Medical Center, Saitama; Kanagawa Children's Medical Center, Kanagawa; Japan

PT-15 Comparative Assessment of MYCN Gene Dosage and Expression
Tanaka S, Tajiri T, Shono K, Noguchi S, Ihara K, Hara T, Saita S.. Kyushu University, Japan

PT-16 High Specificity for Prognostic Prediction of Neuroblastomas : A Combination of N-MYC Amplification, the Shimada System and HA-RAS/TRK A Expression Increases Predictive Efficiency
Tanaka T, Iehara T, Hosoi S, Sugimoto T, Suita S, Tsuchida Y, Sawada T. National Hospital Kure Medical Center, Hiroshima; Kyoto Prefectural University of Medicine, Kyoto; The Japanese Infantile Neuroblastoma Cooperative Study, The Japanese Advanced Neuroblastoma Cooperative Study, Japan

PT-17 MYCN Gene Gain in Primary Neuroblastoma without Amplification: Mechanisms and Influence on Tumor Evolution

PT-18 Elimination of Amplified MYCN Sequences from Primary Neuroblastoma Tumor Cells through the Formation of Micronuclei

http://www.la-sfop.com/anr2002/PosterSession2.htm (2 sur 7) [17/05/2002 16:54:20]
PT-19  Additional 17q in Neuroblastoma Cell Lines: Analysis of the Smallest Overrepresented Region by FISH
Institut Gustave Roussy, Villejuif, France

PT-20  Sensitive Detection of Chromosome 1p Deletion in Neuroblastoma by Three Color Interphase Fluorescence in Situ Hybridization
Van Roy N, Vandesompele J, De Smet E, Laureys G, De Paepe A, Speleman F.
Ghent University Hospital, Ghent, Belgium

PT-21  Hypermethylation-Mediated Regulation of CD44 Expression in Human Neuroblastoma
Yan P, Balmas Bourloud K, Nenadov Beck M and Gross N.
CHU Vaudois, Lausanne, Switzerland

PT-22  In Vitro and in Vivo NB Expression of Co-Stimulatory Molecules
Corrias MV, Airoldi I, Occhino M, Lualdi S, and Pistoia V.
Istituto G. Gaslini, Genoa, Italy

PT-23  Activation of the N-Myc-Id2-Rb Pathway in Neuroblastoma
Lasorella A and Iavarone A.
Albert Einstein College of Medicine, New York, USA

PT-24  The Tyrosine Kinase Inhibitor CEP2563 (KT8391) Sensitizes TRKB Expressing Neuroblastoma (NBL) Tumors to Chemotherapy
Evans AE, Moriyama H, Ho R, Ruggeri B, Brodeur GM.
The Children's Hospital of Philadelphia, Philadelphia, and Cephalon, Inc.,
West Chester, PA, USA

PT-25  Unambiguous Detection of Tumor Cells in the Bone Marrow from Neuroblastoma Patients - Fantasy or Reality?
CCRI, St. Anna Kinderspital, A-1090 Vienna, Austria

PT-26  Proton NMR Spectroscopy for Monitoring of Neuroblastoma Viability in Vivo and in Vitro
MR Center, Karolinska Hospital, Karolinska Institutet and Stockholm University, Stockholm, Sweden

PT-27  Three Methods of Stem Cell Selection Provide Tumor Cell Purging from Stem Cell Products
Grupp SA, Ash S, Fang J, Pierson G, Gribben J, and Diller L.
Children's Hospital of Philadelphia and Dana-Farber Cancer Institute, Boston, USA

PT-28  Loss of Caspase-8 Expression in Neuroblastoma Cells is not Associated with Resistance to Cell Death Induced by Cytotoxic Drugs or Irradiation
Radü J, Pöttgen C, Sieverts H, Havers W, Eggert A.
University Children's Hospital of Essen, Germany

PT-29  Drug-Induced Apoptotic Pathways in Caspase 8 Silenced Neuroblastoma Cells
CHUV, Institute of Biochemistry, Lausanne University, Laboratory of Oncology, University Hospital, Zürich, Switzerland

PT-30 Activation of TRKB Mediates Cytoprotection against Chemotherapy in Neuroblastoma
Jaboin J, Van de Geijn G, Kim CJ, Kaplan D and Thiele CJ.
National Institute of Health, Bethesda, MD, USA and Montreal Neurological Institute, Montreal, Canada

PT-31 Interferon-γ Elevates Caspase-8 Expression and Sensitizes Human Neuroblastoma Cells to TRAIL-Mediated Apoptosis
Faculty of Medicine, University of Tromsø, Norway and Karolinska Institutet, Stockholm, Sweden

PT-32 Arsenic Trioxide-Induced Cell Death Mechanisms in Human Neuroblastoma Cells
Karlsson J, Øra I, Pörn-Ares I and Pählman S.
Lund University, Malmö, Sweden

PT-33 Inducible MYCN Enhances DNA Synthesis, Spontaneous Apoptosis, and Drug-Sensitivity in a MYCN non-Expressing Neuroblastoma Cell Line
Goto H, Alfaro PA, Weiss WA, Reynolds CP.
Childrens Hospital Los Angeles and University of Southern California Keck School of Medicine, Los Angeles, CA; University of California, San Francisco, CA, USA

PT-34 Pyrazoloacridine Induces both Apoptosis and Necrosis, and Is Active in Multi-Drug-Resistant Neuroblastoma Cell Lines with non-Functional p53
Keshelava N, Reynolds CP.
Childrens Hospital Los Angeles and University of Southern California Keck School of Medicine, Los Angeles, CA, USA

PT-35 Assessment of Spontaneous and Chemotherapy Induced Apoptosis in Short Term Cultures of Primary Neuroblastoma (NB) Tissue
Sieverts H, Pietrzak A, Elsesser S, Peretyatko N and Zachariou Z.
University Children's Hospital Heidelberg, and University of Heidelberg, Germany

PT-36 Cisplatin Sensitivity, DNA Adduct Formation and p53 Functional Status in Neuroblastoma Cell Lines
University of Newcastle, U.K

PT-37 Characterization of a Neuroblastoma Xenograft whose Resistance to Irinotecan was Acquired in Vivo in a Therapeutic Setting
Institut Gustave-Roussy, Villejuif ; C.A. Vautrin, Nancy ; Aventis, Vitry/Seine ; France. Netherland Cancer Institute, Amsterdam, Netherlands

PT-38 12-Lipoxygenase Mediates Induction of Reactive Oxygen Species in Fenretinide-Induced Apoptosis of Neuroblastoma
University of Newcastle upon Tyne, UK, University Tor Vergata, Rome, G.Gaslini Children's Hospital, Genoa, Italy

PT-39 Regulation of Retinoic Acid Induced Differentiation of Neuroblastoma by SRC Kinase
Dey N, De PK, Robertson KA and Durden DL. Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA

PT-40 RARγ Protects Neuroblastoma Cells from Fenretinide - Induced Apoptosis but Increases Cell Death with Natural Retinoids
Gorbanov BB, Campbell-Hewson Q, Rana B, Ranalli M, Lovat P, Redfern C. University of Newcastle upon Tyne, UK and University of Tor Vergata, Rome, Italy

PT-41 Growth Inhibitory Retinoid to the Retinoic Acid?Effects Follow Recruitment of Retinoid X Receptor β Promoter
Cheung B, Yan J, Smith S, Kavallaris M, Norris M, Haber M and Marshall G. Children's Cancer Institute Australia for Medical Research, Sydney Australia

PT-42 Ro 13-6307, a Novel Retinoid for Neuroblastoma Differentiation Therapy?
Ponthan F, Klevenvall L, Johnsen JJ, Kogner P. Childhood Cancer Research Unit, Karolinska Institutet, Stockholm, Sweden

PT-43 Inhibition of Neuroblastoma-Induced Angiogenesis by Fenretinide
Ribatti D, Alessandri G, Raffagliello L, Cosimo E, Montaldo PG, Vacca A, Ponzoni M. University of Bari; Institute of Microbiology, University of Brescia; G. Gaslini Children's Hospital, Genoa, Italy

PT-44 Potentiation of RA-Induced Growth Arrest or Apoptosis of Neuroblastoma by Trichostatin A at IC50 or Lower Concentrations
Rikiishi T, Inazumi M, Stauffer J, Inuma K, Thiele CJ and Hayashi Y. Department of Pediatric Hematology and Oncology, Department of Pediatrics, Tohoku University School of Medicine, Sendai, Japan; National Institute of Health, Bethesda, MD, USA

PT-45 A Clusianon-Derivative is a Potent Novel Compound with Cytotoxic Activity in Neuroblastoma Cells
Díaz-Carballo D, Lindtner B, Hilger R, Seeber S, Drothler A, Schramm A, Havers W, Eggert A. University Children's Hospital of Essen, Germany

PT-46 Betulinic Acid and its Derivatives: Novel Strategies for the Treatment of Neuroblastoma
Fulda S, Debatin KM. University Children's Hospital, Ulm, Germany

PT-47 Neuroblastoma Directed Therapy by a Rational Prodrug Design of Etoposide as a Substrate for Tyrosine Hydroxylase
Jiang J, Shabat D, Huebener N, Schroeder U, Wrasidlo W, Wenkel J, Lange B, Gaedicke G, Lode HN. Charité Childrens Hospital, Berlin, Germany and School of Chemistry, Tel-Aviv University, Tel-Aviv, Israel

PT-48 The Biphosphonate Zoledronate Reduces Experimental Neuroblastoma Growth by Interference with Tumor Angiogenesis
Bäckman U, Green J and Christofferson R. Novartis Pharma A-G, Basel, Switzerland, and Children's Hospital, Uppsala University, Sweden

PT-49 A New Biological Approach to Study the Synergism of Hyperthermia and Cisplatinum Against LAN1 Neuroblastoma Cells: Differential Gene Expression Analyzed by Oligonucleotide Arrays
Schramm A, Schulte JH, Klein-Hitpass L, Kremens B, Havers W, Eggert A

PT-50 Growth Inhibition of Neuroblastoma Cell Lines by the Tyrosine Kinase Inhibitor STI571
PT-51  A Novel Syngeneic Murine Model for Thoracic Neuroblastoma  
Corrias MV, Bocca P, Cilli M, Pistoia V and Gambini C.  
Istituto G. Gaslini; Istituto Nazionale per la Ricerca sul Cancro; Genoa, Italy

PT-52  A New Generation of non-Toxic Tumor Targeted Anticancer Agents  
Pecere T, Bet A, Salata C, De Bernardi B, Carli M, Palà G.  
Medical School,University of Padova, Children Hospital G. Gaslini, Genova, Italy

PT-53  Selective Inhibition of the Metastatic Growth of Neuroblastoma Cells by  
Immunoliposomes Containing Doxorubicin  
Pastorino F, Brignole C, Marimpietri D, Moase EH, Allen TM and Ponzoni M.  
G. Gaslini Children's Hospital, Genoa, Italy and University of Alberta, Edmonton, Canada

PT-54  A Xenograft Model of Human Neuroblastoma Bone Metastases in  
Immunodeficient (SCID) Mice  
Childrens Hospital Los Angeles and University of Southern California, Los Angeles, CA, USA

PT-55  Antagonism of Buthionine Sulfoximine Cytotoxicity for Human  
Neuroblastoma Cell Lines by Hypoxia is Reversed by the Bioreductive  
Agent Tirapazamine  
Yang B, Keshelava N, Anderson CP, Reynolds CP.  
Children's Hospital Los Angeles and The University of Southern California, Los Angeles, CA, USA

PT-56  Up-regulation of Erythropoietin in Neuroblastoma by Hypoxia Is Restricted  
to Cells with Neuronal Phenotype  
Rössler J, Stolze I, Frede S, Schweigerer L, Havers W, Fandrey J.  
Universitätsklinikum Essen, Germany

PT-57  TRAIL-Induced Apoptosis is Inhibited by Bcl-2 in Type II Neuroblastoma  
Cells  
Fulda S, Debatin KM.  
University Children's Hospital, Ulm, Germany

PT-58  Smac Peptides or Smac Gene Transfer: Novel Strategies to Overcome  
Resistance of Neuroblastoma Cells against Anticancer Drug- or  
TRAIL-Induced Apoptosis  
Fulda S, Debatin KM.  
University Children's Hospital, Ulm, Germany

PT-59  Dimeric Anti-GD2 Small Immunoproteins as Potential Therapeutic Tools for  
Neuroblastoma  
Occhino M, Corrias MV, Burrone O, Pistoia V, and Bestagno M.  
ICGEB, Trieste; Gaslini Children's Hospital, Genova; Italy

PT-60  Vaccination with Minigenes Encoding for Novel "Self" Antigens Are  
Effective in DNA-Vaccination against Neuroblastoma  
Huebener N, Schroeder U, Lemmel C, Rammensee HG, Wrasidlo W,  
Wenkel J, Lange B, Jiang J, Gaedicke G, Lode HN.  
Charité Childrens Hospital, Berlin; University of Tübingen, Tübingen; Germany

PT-61  Study of IL-15 and/or IL-12 Gene Transfer in Murine NB
PT-62  STK15 Can Function as a Surrogate for MYCN in immunotherapy of MYCN-Amplified Neuroblastoma  Nuchtern J and Sarkar A.  Baylor College of Medicine and Texas Children's Cancer Center, Houston, TX, USA

PT-63  Antitumor Activity of Anti-GD2 mAb in a Metastatic Neuroblastoma Model in Vivo  Raffaghello L, Pagnan G, Pastorino F, Brignole C, Cosimo E, Marimpietri D, Montaldo PG and Ponzoni M.  G. Gaslini Children's Hospital, Genoa, Italy

PT-64  Targeted Delivery and Anti-Tumor Effects of Liposomal Antisense Oligonucleotides in Neuroblastoma  Brignole C, Pastorino F, Pagnan G, Marimpietri D, Cosimo E and Ponzoni M.  G. Gaslini Children's Hospital, Genoa, Italy


PT-66  rAAV-Mediated Long-term Liver-Generated Expression of an Angiogenesis Inhibitor Improves Survival in Mice with Metastatic Neuroblastoma  Davidoff AM, Nathwani AC, Spurbeck WW, Ng CYC, Zhou J, and Vanin EF.  St Jude Children's Research Hospital, Memphis, TN, USA

PT-67  Increased Expression of Angiogenic Inhibitors is Associated with Neuroblastoma Differentiation  Katzenstein HM, Liu S, Crawford SE, Weinstein J, and Cohn SL.  Northwestern University, Chicago, IL, USA


PT-69  Lack of Efficacy of Angiostatin in a Human Neuroblastoma Xenograft Model  Joseph JM, Bouquet C, Opolon P, Morizet J, Aubert G, Rössler J, Gross N, Perricaudet M, Vassal G.  Institut Gustave Roussy, Villejuif, France; Universitätklinikum Essen, Germany; CHU Vaudois, Lausanne, Switzerland

PLENARY SESSION 3 : BIOLOGY AND TRANSLATIONAL

8.00 a.m.  CHAIRPERSONS: J MARIS and P. AMBROS
Room “Grands Lacs-Baïkal-Victoria”

8.15 a.m.  TRAIL Pathway-Associated Gene Clusters on 2q33 and 8p21 are Often Methylated in Neuroblastoma
Academic Medical Center, Amsterdam, The Netherlands. The Johns Hopkins Oncology Center, Baltimore, USA and Sophia Children’s Hospital, Rotterdam, The Netherlands

8.35 a.m.  A Novel Mechanism for Potentiation of TRAIL-Induced Apoptosis: Resveratrol Sensitizes Neuroblastoma Cells for TRAIL through p21-Mediated G1 Arrest
OB-16  Fulda S, Debatin KM.
University Children’s Hospital, Ulm, Germany

9.05 a.m.  Structural Analysis of Regions Responsible for the Distinct Functions of TrkA and TrkB in Neuroblastoma (NB)
OB-18  Hishiki T, Minturn JE, Ho R, Ikegaki N, Brodeur GM.
The Children’s Hospital of Philadelphia, PA USA

9.25 a.m.  p73α over Expression in SH-SY5Y Neuroblasts Induced Nuclear Accumulation of Endogeneous p53 Protein
Institut Gustave Roussy, Villejuif, France

9.45 a.m.  NGF Regulates N-myc Levels Via MAP Kinase Pathway in Neuroblastoma
OB-20  Woo CW, Wada RK, Thiele CJ.
National Cancer Institute, NIH and Cancer Research Center of Hawaii and the Kapiolani Health Research Institute, USA

10.05 a.m.  The Role of the MEIS Homeobox Genes in Neuroblastoma Tumorigenesis
OB-21  Geerts D, Schilderink N, Jorritsma G, and Versteeg R.
Academic Medical Centre, Amsterdam, The Netherlands

10.30 a.m.  Break
Coffee & Viennoiserie
PLENARY SESSION 4: BIOLOGY AND TRANSLATIONAL

11.00 a.m.  CHAIRPERSONS: NK CHEUNG and GP TONINI
Room "Grands Lacs-Baikal-Victoria"

11.00 a.m.  PTEN-AKT-MDM2-p53 Axis in Neuroblastoma Therapeutics
OTR-01 Dey N, Su J.D, Erdreich-Epstein A, Reynolds C.P, Moritake H, Sugimoto T,
Durden D.L.
Indiana University School of Medicine, Herman B Wells Center for Pediatric
Research, Indianapolis, IN Childrens Hospital Los Angeles, Los Angeles, CA,
USA and Miyazaki Medical College, Miyazaki, Japan

11.20 a.m.  Identification of Angiogenesis Inhibitors Upregulated in TrkA Transfected
SY5Y Neuroblastoma Cells by Gene Expression Profiling with
Oligonucleotide Arrays
OTR-02 Schramm A, Schulte JH, Klein-Hitpass L, Klenk M, Brodeur GM,
Schweigerer L, Havers W, Eggert A.
University Children's Hospital of Essen, Germany and The Children's Hospital
of Philadelphia, PA, USA

11.40 a.m.  Favorable Neuroblastoma Genes and Molecular Therapeutics of
Neuroblastoma
OTR-03 Tang X, Kim D, Robinson M, Titus T, and Ikegaki N.
The Children's Hospital of Philadelphia, PA USA

12.00 a.m.  Biological Parameters of Disseminated Tumor Cells give Important
Information on the Response to Cytotoxic Treatment and Outcome of Stage 4
Patients
CCRI, St. Anna Kinderspital, Vienna, Austria

12.30 p.m.  Lunch
Room "Les Parcs"
PARALLEL SESSION 3 : TRANSLATIONAL

2.00 p.m.  **CHAIRPERSONS: M. HABER and D. VALTEAU-COUANET**
Room “Grands Lacs-Baïkal-Victoria”

Gene Expression Profiles as a Prognostic Tool for Neuroblastoma
OTR-05
Berwanger B, Bergmann E, Hartmann O, Nielsen D, Kartal A, Gebhard S, Ultsch A, Krause M, Christiansen H and Eilers M.
Institute of Molecular Biology and Tumour Research; University Children's Hospital; Institute for Informatics; Marburg, Germany

2.15 p.m.  The MYCN Oncogene as a Target for Cancer Therapy: Reporter Gene Assay Identification of MYCN Transcriptional Activity Inhibitors
OTR-06
Lu X., Pearson ADJ., Lunec J.
University of Newcastle upon Tyne, Newcastle upon Tyne, UK

2.30 p.m.  Retinoid-Regulated Transcriptional Target Genes in Neuroblastoma Cells
OTR-07
Children’s Cancer Institute Australia for Medical Research, Sydney, Australia

2.45 p.m.  C75 is an Effective Inducer of Apoptosis in Human Neuroblastoma Cells
OTR-08
Fentz AK, David KA.
University of Hamburg, Germany

3.00 p.m.  Identification of a Novel Gene, Nbla0219/BMCC1, with the BNIP2 and Cdc42GAP Homology (BCH) Domain: Possible Pro-Apoptotic Function and Association between High Expression of BMCC1 and Favorable Prognosis in Neuroblastomas
OTR-09
Chiba Cancer Center Research Institute, Chiba ; Shinshu University School of Medicine., Matumoto ; Gunma University School of Medicine, Gunma ; National Institute of Neuroscience, Tokyo; Japan

3.15 p.m.  Induction of Caspase 8 by IFN-γ Renders some NB Cells TRAIL Sensitive but Reveals a Lack of Membrane TR1/TR2 also Contributes to TRAIL Resistance in NB
OTR-10
Yang X, Merchant M, Kontny U, Mackall C, Thiele CJ.
NCI, Bethesda, MD; Children's Hospital, Albert-Ludwigs-University, Freiburg, Germany

3.30 p.m.  Break
Coffee & vienoiseries

CHAIRPERSONS: T. PHILIP and A. EVANS

4.00 p.m.  Role of Host-Derived and Tumor Cell-Derived MMPs in Neuroblastoma Progression
OTR-11
Chantrain C, Shimada H, Coussens L, Shalinsky D, DeClerck YA.
Children's Hospital Los Angeles, University of Southern California ; University of California San Francisco ; Pfizer/Agouron Pharmaceuticals, Inc. La Jolla ; CA, USA

4.15 p.m.  Resistance to Chemotherapy is Mediated by TrkB in Neuroblastomas (NBs)
OTR-12
Ho R, Hishiki T, Minturn JE, Ikegaki N, Evans AE, Brodeur GM.
The Children's Hospital of Philadelphia, PA, USA

4.30 p.m.  New Prognostic Markers in Locoregional and 4S Neuroblastoma: Chromosomal alterations in 3(p) and 11(q)
OTR-13  Spitz R, Hero B, Ernestus K, Berthold F.
Children's Hospital, Cologne, Germany

4.45 p.m.  Dentritic Cells (DC) for NK/LAK Activation : Rationale for Multicellular Immunotherapy in Neuroblastoma (NB)

Institut Gustave Roussy, Villejuif, France

5.00 p.m.  Human Anti-Idiotypic Antibodies against Anti-GD2-Antibody ch 14.18 Cloned by Phage Display as a Possible Tumor Vaccine against Neuroblastoma

OTR-15  Uttenreuther-Fischer MM, Krueger J, Fischer P.
Charite Children's Hospital, Humboldt University, Berlin, Germany
PARALLEL SESSION 4: CLINICAL

2.00 p.m. CHAIRPERSONS: F. BERTHOLD and JM. ZUCKER
Room "Michigan"

2.00 p.m. MYCN Copy Number and Hyperdiploidy: Do They Define a Favourable Prognostic Group in Neuroblastoma Patients between 12 and 24 Months of Age? A COG Study
OC-01 George R, London WB, Maris JM, Cohn SL, Diller L, Look AT. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Children's Oncology Group, University of Florida, Gainesville, FL; The Children's Hospital of Philadelphia, Philadelphia, PA; Northwestern University, Chicago, IL; USA

2.15 p.m. Prognostic Relevance of CD44 and trkA Expression in Localized Neuroblastoma
OC-02 Ernestus K, Hero B, Spitz R, Christiansen H, Schwab M, Berthold M. University of Cologne, Marburg, DKFZ Heidelberg, Germany

2.30 p.m. A Population Based Controlled Trial of Neuroblastoma Screening at One Year of Age in Germany

2.45 p.m. Dumbbell Localised Neuroblastoma

3.00 p.m. Incidence and Time Frame of Regression in Stage 2 and Stage 3 Neuroblastoma
OC-05 Hero B, Simon T, Benz-Bohm G, Scheel-Walter HG, Schilling FH, Berthold F. Universities of Cologne, Tübingen, Stuttgart, Germany

3.15 p.m. Impact of Radiotherapy for High Risk Neuroblastoma: a Children's Cancer Group Study

3.30 p.m. Break
Coffee & vienoiseries

CHIEFPERSONS: B DE BERNARDI and H. RUBIE

4.00 p.m. Neoplastic Contamination of Leukaphereses in Neuroblastoma is Associated with Poor Bone Marrow Response
OC-07 Faulkner LB, Garaventa A, Marchi C, Tintori V, Lacitignola L, Bambi F, Bernini G and De Bernardi B. Meyer Children's Hospital, Firenze, and Gaslini Children's Hospital, Genova; Italy

4.15 p.m. Rationally Designed Hydrolytically Activated Etoposide Prodrugs, a Novel Strategy for the Treatment of Neuroblastoma
OC-08 Lode HN, Lange B, Schroeder U, Huebener N, Jikai J, Wenkel J, Wrasidlo W, Gaedicke G. Charité Children's Hospital, Berlin, Germany
4.30 p.m.  **I-MIBG with Myeloablative Chemotherapy and Autologous Stem Cell Transplant (ASCT) in Refractory Neuroblastoma; a New Approaches to Neuroblastoma Therapy (NANT) Study**

UCSF, San Francisco, CA; University of Michigan, Ann Arbor, MI; University of Philadelphia, PA; Children's Hospital Los Angeles, and USC, Los Angeles, CA, USA

4.45 p.m.  **Cellular Immunotherapy for Neuroblastoma Utilizing CD8+ CTL Clones Genetically Engineered to Express the CE7R Chimeric Immunoreceptor**

OC-10  Park J, Cooper L, Slovak M, and Jensen M.  
Children's Hospital and Regional Medical Center, Fred Hutchinson Cancer Research Center, Seattle WA; City of Hope National Medical Center, Duarte, CA, US

5.00 p.m.  **13-cis-Retinoic Acid Improves Overall Survival Following Myeloablative Therapy for High-Risk Neuroblastoma: a Randomized Children's Cancer Group (CCG) Study**

OC-11  Reynolds CP, Villablanca JG, Gerbing RB, Stram DO, Seeger RC, and Matthay KK.  
Childrens Hospital Los Angeles for the Children's Cancer Group, Arcadia, USA
POSTER SESSION 3 : GENETICS

CHAIRPERSONS: S. COHN and J.BENARD
Room "Léman"

PG-01 A Region on Chromosome 19 Modifies Tumor Susceptibility in a Mouse Model for Neuroblastoma
Hackett C, Mao JH, Ballmain A, DeYoung J, and Weiss WA.
University of California, San Francisco, CA, USA

PG-02 Karyotypic Evolution in Neuroblastoma
University Children's Hospital, Zürich, Bern, Basel, Children's Hospital, Luzern, St. Gallen, Switzerland, The Chaim Sheba Medical Center, Israel

PG-03 Combined 24-color Karyotyping and CGH Analysis Indicates a Predominant Instability of Early Replicating Chromosome Regions in Neuroblastoma
Institut Curie, Paris and Centre Léon Bérard, Lyon, France

PG-04 Neuroblastoma CGH Data Revisited : Identification of Genetic Subgroups by Cluster Analysis
Vandesompele J, Baudis M, De Preter K, Van Roy N, Laureys G, Speleman F
Ghent University Hospital, Belgium and Stanford University Medical Center, Stanford, USA

PG-05 Comparative Geomic Hybridation (CGH) Analysis Identifies New Chromosomal Gains/Losses in Neuroblastoma
Defferrari R, Mazzocco K, Coco S and Tonini GP.
Advanced Biotechnology Center, National Institute for Cancer Research, Genoa, Italy

PG-06 Novel Regions of Allelic Imbalance Identified by Genome-Wide Analysis of Neuroblastoma
Mora J, Cheung NKV, Oplanich S, Chen L, Gerald WL.
Memorial Sloan-Kettering Cancer Center, New York, NY, USA

PG-07 Analysis of CHD5, a New Member of the Chromodomain Family and Candidate 1p36.3 Suppressor Gene in Neuroblastomas
Thompson PM, Gotoh T, White PS, Brodeur GM.
The Children's Hospital of Philadelphia, PA, USA

PG-08 Analyses of Genes in the Neuroblastoma Deletion Region in 1p36; Rare Mutations or Variations in DFFA and UBE4B Genes in Neuroblastoma Tumors
Krona C, Ejeskär K, Abel F, Sjöberg RM, Bjelke J, Björk E and Martinsson T.
Sahlgrenska University Hospital-East, Göteborg, Sweden, and Murdoch Children's Research Institute, Melbourne, Australia

PG-09 Gene Expression Profiling of the 1p36 Region in Neuroblastoma Using cDNA Microarrays
Institut Curie, Paris, and Centre d'Immunologie de Marseille-Luminy, Marseille, France

PG-10 Characterization of Genes Located within a 1 Mbp Smallest Region of Overlapping Deletion in 1p36 in Human Neuroblastoma
PG-11 Positional Cloning of Translocation Breakpoints of a Constitutional 1;17 Translocation in a Neuroblastoma Patient
Henrich K, Bauer A, Westermann F, Savelyeva L, Claas A, Praml C, Berthold F and Schwab M.
Deutsches Krebsforschungszentrum, Heidelberg, Germany

PG-12 Breakpoint Position on 17q Identifies the Most Aggressive Neuroblastoma Tumors
On behalf of the United Kingdom Children's Cancer Study Group

PG-13 Establishment of Immortalized Cell Lines from non-MYCN Amplified Neuroblastomas with t(11;17) Translocations
McConville C, Genus T, Chughtai S, McMullan DJ and Dyer S.
University of Birmingham and Birmingham Children's Hospital, and Birmingham Women's Hospital, Birmingham, UK

PG-14 Identification of Genes Associated with MYCN overexpression in Neuroblastoma Using Microarray-Based Gene Expression Analysis
Alaminos M, Mora J, Cheung NKV, Qin J, Smith A, Gerald W.
Memorial Sloan-Kettering Cancer Center, New York, NY, USA

PG-15 Array CGH Analysis of DNA Copy Number in Primary Neuroblastomas and Cell Lines
Tomioka N, Ohira M, Misra A, Albertson D, Pinkel D, Feuerstein B, Nakagawara A.
Chiba Cancer Center Research Institute, Chiba, Japan, and UCSF Cancer Center, San Francisco, USA

PG-16 Very High Levels of Micro-Foci inducing Virus (MFV) Sequences in Neuroblastomas with MYCN Amplification
Rovigatti U, Keller R, Bachi T, Speleman F and Tam A.
University of Pisa Medical School, Pisa, Italy; Universitatsspital, Zurich, Switzerland, Ghent University Hospital, Ghent, Belgium, and Genelabs, Redwood City, CA, USA

PG-17 Application of Microarray Technology for Evaluation of Gene Copy Number and Gene Expression Profile in Neuroblastoma
National Institute for Cancer Research, Genoa, Italy; The Children's Hospital of Philadelphia, Philadelphia, USA

PG-18 Expression of a Novel Gene Identified in Neuroblastoma Cell Line IMR5 Appears to Depend on its Genomic Coamplification with MYCN
Fischer M, Skowron M, Mehler K, Berthold F
University of Cologne, Germany

PG-19 Co-Amplification of ATBF1 and MYC in Neuroblastoma Cell Line SJNB-12
Ghent University Hospital, Ghent, Belgium

PG-20 Molecular Pathology of Non-MYCN Amplified, Advanced Stage Neuroblastoma
Chughtai S, Genus T, Ramani P, Oude Luttikhuis M and McConville C
On behalf of the UK Children's Cancer Study Group
University of Birmingham & Birmingham Children's Hospital, UK
PG-21 NEDLI/Nbla0078 Identified from the Neuroblastoma cDNA Library Is A Novel E3 Ubiquitin Ligase with the HECT-domain and its Expression is Significantly Associated with Favorable Outcome in Primary Neuroblastomas Miyazaki K, Okamoto Y, Ozaki Y, Sakamoto M, Kato C, Nimura Y, Hirato J and Nakagawara A. Chiba Cancer Center Research Institute, Chiba, Nagoya University School of Medicine, Nagoya and Gunma University School of Medicine, Maebashi, Japan

PG-22 Deletion Mapping at 4p16 Defines a Minimal Deleted Region of 3.0 cM in Human Neuroblastoma Perri P, Longo L, Cusano R, Devoto M, Conte M, Seri M, Tonini GP, Advanced Biotechnology Center; National Institute for Cancer Research; University of Genoa; Gaslini Children's Hospital - Genoa, Italy

PG-23 Comprehensive Analysis of the 9p21 Region in Neuroblastoma Mora J, Alaminos M, Illei P, Cheung NKV, Gerald WL, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

PG-24 Microarray Analysis of Telomerase-Positive versus Telomerase-Negative Neuroblastoma Cell Lines Schaefer K-L, Braun Y, Wai DH, Baer C, Reynolds CP, Boecker W, Dockhorn-Dworniczak B, Selle B, and Poremba C. Gerhard-Domagk-Institute of Pathology, University of Muenster, Muenster; University Children's Hospital of Heidelberg, Heidelberg.; Institute of Pathology, Kempten; Germany, and Children's Hospital Los Angeles, Los Angeles, USA

PG-25 Rearrangements and Increased Expression of Cyclin D1 in Neuroblastoma Molenaar J, van Sluis P, Versteeg R and Caron H. Academic Medical Centre, University of Amsterdam, Netherlands

PG-26 Identification of Three Novel Amplified and Overexpressed Transcripts in Neuroblastoma Vandesompele J, De Preter K, Van Roy N, De Paepe A, Speleman F. Ghent University Hospital, Belgium

PG-27 Identification of Novel Human Neuronal Leucine-Rich Repeat (hNLRR) Family Genes and Reciprocal Association of Expression of Nbla10449/hNLRR-1 and Nbla10677/hNLRR-3 with the Prognosis of Neuroblastoma Hamano S, Ohira S, Fukumura M, Tsunobuchi H, Isogai E, Nakada K and Nakagawara A. Chiba Cancer Center Research, Chiba and St Marianna University School of Medicine, Kawasaki, Japan

PG-28 Identification of Novel Coding Exons within the Neuroblastoma Amplified Gene NAG Scott DK, Pearson ADJ, Lunec J. Cancer Research Unit, University of Newcastle upon Tyne; Royal Victoria Infirmary, Newcastle upon Tyne, UK

PG-29 Mutation and Expression Analysis of the von Hippel-Lindau Gene in Neuroblastoma Hoebeeck J, Vandesompele J, Van Roy N, De Smet E, Laureys G, De Paepe A and Speleman F. Ghent University Hospital, Belgium
POSTER SESSION 4 : CLINICAL

CHAIRPERSONS: R. LADENSTEIN - T. SUGIMOTO
Room "Lugano-Constance"

PC-01 Comparative Genomic Hybridization (CGH) Analysis of Neuroblastoma Associated with Lung, Brain, or Meningeal Metastases
Institut Curie, Paris; Institut Gustave-Roussy, Villejuif, France; USC and Childrens Hospital Los Angeles, Los Angeles; UCSF, San Francisco, CA, USA

PC-02 DNA Index and S Phase as Potential Tools for Profiling Localized and Stage 4S Neuroblastomas
Centre Paul Papin, Angers; Institut Gustave Roussy, Villejuif; Société d'Oncologie Pédiatrique Française, France

PC-03 Comprehensive Analysis of Tumoral DNA Content Reveals Clonal Ploidy Heterogeneity: Clinical and Prognostic Significance in Neuroblastoma
Mora J, Alaminos M, Cheung NKV, Juan G, Illei P, Gerald WL.
Memorial Sloan-Kettering Cancer Center, New York, USA

PC-04 A New Splicing Variant of Tyrosine Hydroxylase: Implications for the Detection of Minimal Residual Disease in Neuroblastoma
Gallego S, Parareda A, Villaescusa JC, Sanchez de Toledo J.
Hospital Universitari Vall d’Hebron, Barcelona, Spain

PC-05 Expression of DNp73 is a Molecular Marker for Adverse Outcome in Neuroblastoma Patients
Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy

PC-06 Quantitation of GD2 Synthase mRNA by Real-Time Reverse Transcription-PCR: Clinical utility in Evaluating Adjuvant Therapy in Neuroblastoma
Cheung IY, LoPiccolo MS, Kushner BH, Kramer K, Cheung KV.
Memorial Sloan-Kettering Cancer Center, New York, NY, USA

PC-07 Improved Real-Time Quantitative PCR Assay Allows Detection of MYCN Amplification in Small Subsets of Neuroblastoma Cells
Ghent University Hospital, Belgium, Centre Léon Bérard, Lyon, France, University of Newcastle, Newcastle upon Tyne, UK

PC-08 P16 Expression is Associated with Advanced Stage Neuroblastoma and not Correlated with Expression of Id2: A Children's Oncology Group Study
Gebauer S, Diccianni MB, Omura-Minamisawa M, Cohn SL, Seeger R and Yu AL.
University of California, San Diego, Northwestern University, Chicago, Children's Hospital, Los Angeles, USA

PC-09 Imaging with Tc-99m-Sestamibi Does not Predict Drug Resistance or Outcome in Childhood Neuroblastoma
PC-10 Detection of tumour cells in bone marrow and peripheral blood from neuroblastoma patient: a comparative study of morphological, histological, immunocytochemical and molecular analyses

Gaslini Children's Hospital and National Institute for Cancer Research, Genova; Meyer Children's Hospital, Firenze; and Civic Hospital, Brescia; Italy

PC-11 Micrometastatic Disease Response Assessment in Neuroblastoma

Negri F, Sementa AR, Garaventa A, Marchi C, Lacitignola L, De Bernardi B, and Faulkner LB.
Giannina Gaslini Children's Hospital, Genova, and Meyer Children's Hospital, Firenze; Italy

PC-12 Quantitative Analysis of Tyrosine Hydroxylase mRNA in Blood and Bone Marrow Follows the Clinical Course of Neuroblastoma

Träger C, Kogner P, Kullman A, Kågedal B.
Linköping University and Childhood Cancer Research Unit, Karolinska Institute, Sweden

PC-13 Clinical Significance of Minimal Residual Disease in Bone Marrow, Blood and Leukapheresis Detected by RT-PCR for the Tyrosine Hydroxylase in Stage 4 Neuroblastoma: a French Pilot Study

Institut Gustave Roussy, Villejuif; Institut Curie, Paris, France

PC-14 Bone Marrow Anti-GD2 Immunocytology Identifies a Substantial Proportion of Chemotherapy-Resistant Patients

Meyer Children's Hospital, Firenze, and Gaslini Children's Hospital, Genova; Italy

PC-15 TH, Gage and Mage as MRD Markers in Neuroblastoma

Fernández JM, Oltra S, Cañete A, Orellana C, Martínez-Castellano F, Castel V.
Hospital "La Fe", Valencia, Spain

PC-16 Bone Marrow (BM) Cytogenetic Abnormalities in Patients with High-Risk Neuroblastoma (NB)

Kramer K, Kushner BH, Jhanwar SC, Cheung NKV.
Memorial Sloan-Kettering Cancer Center, NY, USA

PC-17 Evolving Significance of Prognostic Markers Associated with Treatment Improvement Stage 4 Neuroblastoma

Mora J, Gerald WL, Qin J, and Cheung NKV.
Memorial Sloan-Kettering Cancer Center, New York, NY, USA

PC-18 Efficacy and Safety of Ex Vivo Bone Marrow (BM) Purging of Neuroblastoma (NB) Using Anti-GD2 Antibody 3F8

Cheung I, LoPiccolo S, Collins N, Kushner B, Cheung NK.
Memorial Sloan-Kettering Cancer Center, New York, NY, USA

PC-19 Immunomagnetic Purging of Neuroblastoma from Peripheral Blood Stem Cells Concentrated by Carbonyl Iron Magnetic Fractionation

Tang YM, Billups C, Seeger RC, Villablanca JG, Reynolds CP.
Childrens Hospital Los Angeles and University of Southern California Keck School of Medicine, Los Angeles, CA; Childrens Oncology Group, USA
| PC-20 | Purging Neuroblastoma Cells from Bone Marrow or Peripheral Blood Using a VDEPT Method with Rabbit Carboxylesterase and CPT-11: Application to Specimens with >1% Tumor Burden  
Wagner LM, Potter PM, Danks MK.  
St. Jude Children's Research Hospital, Memphis, TN, USA |
| PC-21 | Phase I Trial of Oral [N-(4-hydroxyphenyl) retinamide] (4-HPR) in Children with Resistant/Recurrent Solid Tumors: A Children's Cancer Group Study (CCG 09709)  
Villablanca JG, Ames MM, Reid JM, Bagniewski P, Krailo M, Reynolds CP.  
University of Southern California, Los Angeles, CA; Mayo Clinic, Rochester, Minnesota; Children's Cancer Group, Arcadia, CA, USA |
| PC-22 | Phase I Trial of Fenretinide in Children with Neuroblastoma  
Gaslini Children's Hospital, Genova; National Cancer Institute, and European Institute of Oncology, Milano, Italy |
| PC-23 | Pilot Study of Buthionine Sulfoximine (BSO) Combined with Non-Myeloablative Melphalan (L-PAM) in Refractory Neuroblastoma  
Anderson CP, Seeger RC, Bailey HH, Reynolds CP.  
Children's Hospital of Los Angeles and University of Southern California, Los Angeles, CA; University of Wisconsin, Madison WI, USA |
| PC-24 | Lymphotactin (Lptn) and IL-2 Gene-Modified Allogenic Tumor Vaccine in Patients with Advanced Neuroblastoma  
Baylor College of Medicine, Houston, TX; St. Jude Children's Research Hospital, Memphis, TN, USA |
| PC-25 | Oral Topotecan Therapy for Relapsed or Refractory Neuroblastoma (NB)  
Kramer K, Kushner BH, Cheung NKV.  
Memorial Sloan-Kettering Cancer Center, New York, NY, USA |
| PC-26 | A Phase-II-Study with Topotecan and Etoposide in Relapsed Neuroblastoma  
Längler A, Hero B, Berthold F.  
Children’s hospital, University of Cologne; Germany |
| PC-27 | Irinotecan and High-Dose Cyclophosphamide (HD-CPM) for Neuroblastoma (NB)  
Brian H. Kne,Kushner BH, Kramer K, Cheung NKV.  
Memorial Sloan-Kettering Cancer Center, New York, NY, USA |
| PC-28 | Phase II study of High Dose 131 I-MIBG with Hematopoietic Stem Cell Transplant (HSCT) in Refractory Neuroblastoma  
Univ of California San Francisco, CA, , and CHOP/ Univ. Penn., Philadelphia, PA |
| PC-29 | Topotecan plus Myeloablative Thiotepa and Carboplatin for Neuroblastoma (NB)  
Kushner BH, Kernan NA, Kramer K, Reich L, Boulad F, Cheung NKV.  
Memorial Sloan-Kettering Cancer Center, New York, NY, USA |
| PC-30 | Treatment of Metastatic Neuroblastoma (NB) with Anti-GD2 Murine Monoclonal Antibody 3F8: The Hong Kong Experience  
Chan GCF, Shing MMK, Luk CW, Ling SC, Lee ACW  
Hong Kong Paediatric Haematology / Oncology Study Group, Hong Kong |
Ch14.18 Anti-GD 2 Antibody Treatment in High Risk Neuroblastoma. Results of 2 Consecutive Phase II Studies
St. Anna Kinderspital, Vienna, Austria, Giannina Gaslini Children's Hospital, Genova, Italy, University Tübingen, Germany

Anti-GD2 Antibody 3F8 and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), plus 13-Cis-Retinoic Acid (CRA), for Maintenance of Complete/Very Good Partial Remission (CR/VGPR) of Neuroblastoma (NB)
Kushner BH, Kramer K, Cheung NKV.
Memorial Sloan-Kettering Cancer Center, New York, NY

Final Report on a Randomized Phase II Study of s.c. IL 2 after MGT/SCR in Stage 4 Neuroblastoma
Study center: CCRI/ St. Anna Children's Hospital, Vienna, Austria

Treatment Optimization in N8 with the Goal to Eradicate Minimal Residual Disease (MRD) while Preventing CNS Relapse and Treatment-Related Leukemia
Cheung NKV, Kushner BH, LaQuaglia M, Kramer K, Wolden SL, Kernan NA.
Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Autologous Hematopoietic Stem Cell Transplant (AH SCT) before Disease Progression in Children in Stage IV Neuroblastoma Diagnosed after the First Year of Life
Children's Hospital Los Angeles, USA

Myeloablative Therapy with Purged Autologous Hematopoietic Stem Cell Transplant (AH SCT) for Stage 4 Neuroblastoma Diagnosed after One Year of Age in Partial Response (PR) after Induction Therapy
Children's Hospital Los Angeles and Keck School of Medicine, USC, Los Angeles, CA, USA

Rapid Sequence Tandem Transplant For Advanced Neuroblastoma: Update and Patterns of Relapse
Children's Hospitals of Philadelphia, Atlanta and Boston; and Dana-Farber Cancer Institute, Boston, USA

Intensified Multimodal Therapy Improves Survival in High-Risk Neuroblastoma
Karolinska Hospital, Huddinge University Hospital, Karolinska Institutet, Stockholm Sweden

Epidemiological Aspects in the German Neuroblastoma Screening Project
Johannes Gutenberg University, German Childhood Cancer Registry, Mainz; University of Cologne, Children's Hospital, Cologne; University of Hamburg, University Hospitals Eppendorf, Hamburg; Landesgesundheitsamt Niedersachsen, Hannover; Klinikum Stuttgart, Olghospital, Stuttgart; Germany

Neuroblastoma (NB) Screening at 12 Months. French Study from 1995 to 1997
PC-41 Neuroblastic Tumors (NT) and Opsoclonus-Myoclonus Syndrome (OMS). The Italian Experience in a 16-year Period

PC-42 Neonatal Localized Neuroblastoma

PC-43 Disseminated Neuroblastoma in Children Older than 1 Year at Diagnosis. Comparable Results with 3 Consecutive High-Dose Protocols of the Italian Cooperative Group for Neuroblastoma (ICGNB)

PC-44 Results of Risk Adapted Treatment According to the Austrian Neuroblastoma Trial A-NB94
Ladenstein R, Poetschger U, Ambros PF, Gadner H For the Austrian Cooperative Pediatric Oncology Group (AGPHO) St. Anna Kinderspital, Vienna, Austria

PC-45 Treatment Strategy for Neuroblastoma Infants in Japan
Iehara T, Hamazaki M, Tanaka T, Hosoi H, Sawada T, Sugimoto T. On behalf of the Japanese Infantile Neuroblastoma Cooperative Study Group The Japanese Infantile Neuroblastoma Cooperative Study Group and Kyoto Prefectural University of Medicine, Kyoto, Japan

PC-46 Neuroblastoma in a Multiracial Asian Population- a Combined Singapore and Malaysian Perspective
Rajalingam V, Yong MH, Lin HP, Ariffin H, Knight L, Tan AM, Chan MY, Quah TC. KK Women’s and Children’s Hospital, National University Hospital, Singapore and University Hospital, Malaysia

PC-47 Increased Incidence of Congenital Cardiovascular Malformations in Patients with Neuroblastoma
George R, Lipshultz SE, Lipsitz SR, Colan SD, Diller L. Harvard Medical School, Boston MA, University of Rochester Medical Center, Rochester, NY, Medical University of South Carolina, Charleston, SC, USA

PC-48 Radiographic Assessment of Resectability of Locoregional Disease in Children with High-Risk Neuroblastoma During Neoadjuvant Chemotherapy
Davidoff AM, Corey BL, Rao BN, Hoffer FA, Bowman LC, Furman WL, Santana VM and Shochat SJ. St. Jude Children's Research Hospital, Memphis, Tennessee, USA

PC-49 The Role of Surgery in Stage 4 Neuroblastoma
Castel V, Tovar JA, Costa E, Cañete A, Cuadros J, Ruiz-Jimenez JI. On behalf of the Spanish Neuroblastoma Group

PC-50 Localized Cervical Neuroblastoma

PC-51 Long Term Results and Risk Profile in Stage 4 Neuroblastoma over 1 Year of Age

PC-52 Hearing Loss in Long-Term Survivors of Neuroblastoma
Simon T, Hero B, Dupuis W, Selle B, Berthold F.
Children's Hospital, Cologne, Karlsruhe, Heidelberg, Germany

PC-53 Neuropsychological and Psychosocial Resiliency in Children Treated for Neuroblastoma
Carpentieri SC, Diller L.
Dana-Farber Cancer Center, Children's Hospital, Boston, and Harvard Medical School, Boston MA, USA

PC-54 Second Tumour after Radiometabolic Therapy for Neuroblastoma. a Mono-Institutional Experience
Gaslini Children's Hospital, Galliera Hospital, Genova; University of Catania; Civic Hospital, Alessandria; Italy

PC-55 MLL Translocation in Treatment-Related all Emerged after Marrow Harvest and before Radioimmunotherapy during N7 Neuroblastoma Treatment
Raffini LJ, Cheung NKV, Rappaport EF, Felix CA.
Children's Hospital of Philadelphia, Philadelphia, PA and Memorial Sloan-Kettering Cancer Center, New York, NY, USA
PLENARY SESSION 5: TRANSLATIONAL

8.00 a.m. CHAIRPERSONS: K. MATTHAY and A. PEARSON
Room “Grands Lacs-Baikal-Victoria”

8.15 a.m.
Gene Expression Profiling of Neuroblastoma Clinicobiological Correlation
OTR-16
Mora J, Cheung NKV, Alaminos M, Qin J, Smith A, Gerald WL Memorial Sloan-Kettering Cancer Center, New York, NY, USA

8.30 a.m.
GADD153 and Bak, Novel Molecular Targets of Fenretinide-Induced Apoptosis of Neuroblastoma and the Synergistic Response with Chemotherapeutic Drugs
OTR-17
Lovat P, Oliverio S, Goranov B, Pearson A, Piacentini M and Redfern C. University of Newcastle upon Tyne, UK and University of Tor Vergata, Rome, Italy

8.45 a.m.
Fenretinide (4-HPR) and 4-HPR + Safingol Prolong Survival in a Xenograft Model of Human Neuroblastoma
OTR-18
Maurer BJ, Sun BC, Frigala T, Vlckova J, Ernst WA, Gupta S, Vishnuvajjala BR, Reynolds CP. Childrens Hospital Los Angeles, University of Southern California, Los Angeles, CA; Molecular Express, Los Angeles CA; National Cancer Institute, Bethesda, MD, USA

9.00 a.m.
Antitumor Activity of Immunologically-Targeted Liposomal Fenretinide in Human Neuroblastoma
OTR-19
Raffaghello L, Pagnan G, Pastorino F, Brignole C, Cosimo E, Marimpietri D, Montaldo PG and Ponzoni M. G. Gaslini Children's Hospital, Genoa, Italy

9.15 a.m.
Association of Mutant p53 with Multidrug Resistance in Neuroblastoma Cells
OTR-20
Norris MD, Xue C, Flemming C, Lock RB, Marshall GM, Haber M. Children's Cancer Institute Australia for Medical Research, Sydney Australia

9.30 a.m.
Increased Incidence of TP53 Mutations in Post-Treatment Neuroblastoma
OTR-21
Keshelava N, Chen P, Waidyaratne NS, Seeger RC, Triche TJ, Reynolds CP. Childrens Hospital Los Angeles and University of Southern California Keck School of Medicine, Los Angeles, CA; Childrens Cancer Group, USA

9.45 a.m.
Inhibition of Angiogenesis in Neuroblastoma by VEGF-Trap
OTR-22

10.00 a.m.
Activity of Temozolomide in Relation to DNA Repair in Neuroblastoma
OTR-23

10.15 a.m.
Break
Coffee & Viennoiserie
PLENARY SESSION 6 : CLINICAL

10.45 a.m.  CHAIRPERSONS: O. HARTMANN and R. SEEGER  
Room "Grands Lacs-Baïkal-Victoria"

10.45 a.m.  Surgery as Only Treatment for INSS Stage 2 Neuroblastoma without MYCN Amplification: Final Report; an European Prospective Trial  
OC-12  
For the LNESG, Institut Curie, Paris, France

11.00 a.m.  Localized Neuroblastoma and Myc-N Amplification : Improved Survival with High-Dose Chemotherapy and Locoregional Irradiation  
OC-13  
Hôpital des Enfants, Toulouse, for the SFOP, France

11.15 a.m.  Prediction of Outcome in Stage 4 Neuroblastoma by MIBG Scintigraphy Score  
OC-14  
Matthay K, Edeline V, Tanguy ML, Lumbroso J, Zucker JM, Valteau D, Hartmann O, Michon J.  
University of California, San Francisco, CA, USA; Institut Curie, Paris; Institut Gustave Roussy, Paris, France

11.30 a.m.  Results of NB 97 SFOP Protocol in Children > 1 Year with a Stage 4 Neuroblastoma  
OC-15  
Valteau-Couanet D, Michon J, Perel Y, Bergeron C, Rubie H, Coze C, Rodary C, and Hartmann O.  
For the SFOP Neuroblastoma Group

11.45 a.m.  A Pilot Trial of a GD-2 Directed Anti-Idiotype Antibody as a Vaccine for High Risk Neuroblastoma  
OC-16  
University of California in San Diego; Baylor College of Medicine; University of Maryland in Baltimore; University of Alabama in Birmingham; University of Texas Southwestern Medical School; University of California San Francisco; Dana Farber Cancer Institute, USA

12.00 a.m.  Oral ß-Glucan Synergizes with Intravenous Monoclonal Antibody 3F8 in the Therapy of Neuroblastoma  
OC-17  
Modak S and Cheung NKV.  
Memorial Sloan-Kettering Cancer Center, New York, NY, USA

12.15 p.m.  G. BRODEUR: CLOSING REMARKS